Bioscience

Capstone Therapeutics announces continuation of AZX100 phase 2 clinical trial

July 6, 2010

By Flinn Foundation

[Source: Market Watch] – Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from its ongoing AZX100 Phase 2a clinical trial in trocar site scarring following arthroscopic shoulder surgery. Based on this analysis, the clinical trial will continue to its planned 12-month endpoints. 

For more information: Capstone Therapeutics Announces Continuation of AZX100 Phase 2 Clinical Trial in Dermal Scarring Following Shoulder Surgery